Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV businessPoint-of-Care product revenue ...
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback